Food and Drug Administration
Center for
Drug Evaluation and Research
SUMMARY
MINUTES OF THE
Matthew Rudorfer, M.D.
(Acting Chair)
Tana Grady-Wilky, M.D.
Richard Malone, M.D.
Irene Ortiz, M.D.
Jean Bronstein
FDA Participants
Russell
Katz, M.D.
Judith A. Racoosin, M.D.,
M.P.H.
Tarek
A. Hammad, M.D., Ph.D.
Executive Secretary
Anuja M. Patel, M.P.H.
Paul
Keck, M.D.
Andrew
Leon, Ph.D.
Neal
Ryan, M.D.
Philip
Wang, M.D.
Sheila Weiss, Ph.D.
Ellen Leibenluft, M.D.
Industry Representative (Non-voting)
Dilip Mehta, M.D., Ph.D.
These
summary minutes for the
I certify that I attended the
____________________________ ____________________________
Anuja M. Patel, M.P.H. Matthew Rudorfer, M.D.
Executive
Secretary Chair
The meeting was called to order by Matthew Rudorfer, M.D., Acting Committee Chair, and the conflict of interest statement was read into the record by Anuja Patel, Executive Secretary.
Lynn Goldman, M.D.
Maureen Schweers (National
Discussions on the white blood cell (WBC) monitoring schedule for patients being treated long-term with clozapine. Currently, the WBC monitoring schedule is weekly for the first six months of continuous therapy and biweekly thereafter. The committee considered the question of whether the frequency of WBC monitoring can be diminished further following some period of biweekly monitoring.
FDA Presentation
Overview of Issues Judith
A. Racoosin, M.D., M.P.H.
Safety
Team Leader, Division of
Neuropharmacologic
Drug Products, FDA
Sponsor Presentations
Novartis
Pharmaceuticals Corporation
· Introduction James
Rawls, Pharm. D.
Associate Director
Drug Regulatory Affairs
Novartis Pharmaceuticals Corporation
·
Overview of Agranulocytosis
Chief, Division of Hematology and Oncology
Department of Medicine
·
Clozaril Registry Data Vinod
Kumar, M.D.
Executive Director,
Clinical Development and Medical Affairs
Novartis Pharmaceuticals Corporation
·
Quantitative Analysis of US Data Lawrence
Hauptman, M.D.
Director, Drug Regulatory Affairs
Novartis Pharmaceuticals Corporation
·
Summary and Conclusion John
M. Kane, M.D.
Professor of Psychiatry,
Neurology and Neuroscience
FDA Presentation
·
Discussion of Selected Safety Data Tarek
A. Hammad, M.D., Ph.D.
Safety Medical Reviewer,
Division of Neuropharmacologic
Drug Products, FDA
Questions
to the Committee:
1. Should the frequency of WBC
monitoring be further reduced after some duration of biweekly monitoring, and
if so, when and what reduced frequency of WBC monitoring would be acceptable?
The Committee’s consensus was that the
frequency of WBC monitoring could be reduced at some point following bi-weekly
monitoring; however, the members were unsure as to precisely when this change
could take place. Data from the United
Kingdom and Australia, where patients are monitored monthly after some defined
point in time, appear to support a change to monthly monitoring since, in these
countries, no excessive increase in agranulocytosis rates were seen. Regarding when to effect the change, the
committee expressed comfort with recommending that a change could be made
following 12 to 24 months of therapy.
However, they further agreed that any changes in schedule should only be
made for patients whose WBCs have shown to be consistent and within normal
range. In spite of their
recommendations, the committee acknowledged that if the monitoring interval
were expanded to monthly intervals, they would anticipate that there will be an
increase seen in the rate of agranulocytosis.
The Committee suggested that
the registries for the marketed generic products (each generic firm operates
its own independent registry) and the Clozaril registry be interfaced so that
patients who switch to and from generics can be captured in one data base and
thus their data integrated.
·
Should white blood cell (WBC) monitoring stop altogether at some time
point, and if so when?
No. The overwhelming consensus of the Committee was that mandatory WBC
monitoring should not stop.
· Should the program be
changed overall, e.g., should it become voluntary, as is most advice in
labeling regarding monitoring for adverse events?
No. The
overwhelming consensus of the Committee was that the mandatory program should not
be changed significantly, nor should it become voluntary. WBC monitoring is
essential for patients using clozapine.
2. Should the absolute
neutrophil count (ANC) be required as a part of WBC monitoring?
Yes. The overwhelming
consensus of the Committee was that, as is required in the
Following completion of
discussion of the questions, the committee adjourned at